中国医药：2024年净利同比预减45%—68%

Core Viewpoint - China Medical (600056) expects a significant decline in net profit for the fiscal year 2024, projecting a range of 335 million to 576 million yuan, which represents a year-on-year decrease of 68% to 45% [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of 335 million to 576 million yuan for 2024, indicating a substantial reduction compared to the previous year [1] - The projected decrease in net profit is attributed to various operational challenges faced by the company [1] Group 2: Corporate Changes - The company received a notification from its important associate, Chongqing Yijian, regarding the transfer of 2% equity held by Chongqing Chemical Group to General Technology Group, which has been completed with the necessary registration [1] - Following this transfer, General Technology Group now holds 24% of Chongqing Yijian, while the company and General Technology Group together hold a combined 51% stake, resulting in a change of controlling shareholder to General Technology Group and the actual controller to the State-owned Assets Supervision and Administration Commission of the State Council [1]